Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Myocardial Infarction Treatment Pipeline Review H2 2016

Sunday, October 30, 2016 23:26
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Myocardial Infarction – Pipeline Review, H2 2016’, provides an overview of the Myocardial Infarction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/711807-myocardial-infarction-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myocardial Infarction

 

Reasons to buy

 

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Complete report details @ https://www.wiseguyreports.com/reports/711807-myocardial-infarction-pipeline-review-h2-2016

 

Table of Contents
Table of Contents 2
Introduction 6
Myocardial Infarction Overview 7
Therapeutics Development 8
Myocardial Infarction – Therapeutics under Development by Companies 10
Myocardial Infarction – Therapeutics under Investigation by Universities/Institutes 15
Myocardial Infarction – Pipeline Products Glance 17
Myocardial Infarction – Products under Development by Companies 21
Myocardial Infarction – Products under Investigation by Universities/Institutes 27
Myocardial Infarction – Companies Involved in Therapeutics Development 29
Myocardial Infarction – Therapeutics Assessment 87
Drug Profiles 104
Myocardial Infarction – Dormant Projects 319
Myocardial Infarction – Discontinued Products 328
Myocardial Infarction – Product Development Milestones 329
Appendix 343

 

Get It now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=711807

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)        

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.